



January 3, 2013

## **Esperion to present at 31st Annual J.P. Morgan Healthcare Conference**

PLYMOUTH, MI [Jan 3, 2013] - Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced that company founder Roger Newton, Ph.D., will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco. Dr. Newton's presentation will take place on Tuesday, January 8, at 3 PM PST in Elizabethan C/D Room 120 of the Westin St. Francis Hotel.

### **About Esperion Therapeutics**

Esperion Therapeutics, Inc. discovers and develops novel therapies for the treatment of cardiometabolic diseases. The company's lead product candidate, ETC-1002, is an AMP kinase activator and ATP citrate lyase inhibitor that is being evaluated in multiple Phase 2 clinical trials for the treatment of hypercholesterolemia and other cardiometabolic risk factors.

Esperion intends to commercialize innovative, first-in-class therapies focused on enhancing lipid regulation, addressing statin intolerance and improving overall cardiometabolic health. For more information, please visit [www.esperion.com](http://www.esperion.com).

Media Contact

Andrea Coan

Berry & Company Public Relations

212-253-8881

[acoan@berrypr.com](mailto:acoan@berrypr.com)